flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Newly described process in Parkinson’s protein as a potential new therapy route

An international group of researchers led by Professor Wim Versées (VIB-VUB) has unraveled the workings of an essential mechanism in ‘Parkinson’s protein’ LRRK2. Their study demonstrates a direct link between the protein’s ‘dimerization’ – two copies that are bound together –and mutations that lead to Parkinson’s disease. This process could eventually lead to a promising therapy route. This research has been published in the leading academic journal Nature Communications.

Research | 19 October 17
Read more
19
Oct
2017

Imec en de UGent openen HomeLab

Gisteren openden imec en de UGent op het technologiepark in Zwijnaarde HomeLab, een digitale leef- en leeromgeving die de woning van de toekomst als uitgangspunt neemt – en waar bedenkers, designers, ontwikkelaars en testgebruikers slimme diensten en producten kunnen ontwikkelen en/of testen.

19
Oct
2017

ONTOFORCE wins the EIT Venture Award 2017

ONTOFORCE has won the EIT Venture Award 2017 for its semantic search platform DISQOVER. This award – one of three awarded by the European Institute of Innovation & Technology – recognises Europe’s most promising ventures. The jury acknowledged ONTOFORCE’s passion and societal impact in democratizing Big Data in Life Sciences, and beyond.

19
Oct
2017

Ablynx announces launch of proposed global offering

Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need, announced today that it intends to offer and sell, subject to market and other conditions, approximately $175 million of its ordinary shares in a global offering, which is comprised of a public offering in the United States and Canada of ordinary shares in the form of American Depositary Shares ("ADS"), and an offer of ordinary shares in Europe and countries outside of the United States and Canada in a concurrent private placement. Investors other than qualified investors under applicable law will not be eligible to participate in this private placement.

19
Oct
2017

Kankercongres.be: Meer dan 300 deelnemers krijgen op 21 oktober meer informatie over kankeronderzoek en toekomstige behandelingen

Meer dan 300 patiënten, artsen, wetenschappers en industrievertegenwoordigers komen op 21 oktober naar Gent voor het eerste kankercongres. Inschrijvingen lopen nog tot 20 oktober of ter plaatse.

19
Oct
2017

Imec en de UGent openen HomeLab

Gisteren openden imec en de UGent op het technologiepark in Zwijnaarde HomeLab, een digitale leef- en leeromgeving die de woning van de toekomst als uitgangspunt neemt – en waar bedenkers, designers, ontwikkelaars en testgebruikers slimme diensten en producten kunnen ontwikkelen en/of testen.

19
Oct
2017

ONTOFORCE wins the EIT Venture Award 2017

ONTOFORCE has won the EIT Venture Award 2017 for its semantic search platform DISQOVER. This award – one of three awarded by the European Institute of Innovation & Technology – recognises Europe’s most promising ventures. The jury acknowledged ONTOFORCE’s passion and societal impact in democratizing Big Data in Life Sciences, and beyond.

19
Oct
2017

Ablynx announces launch of proposed global offering

Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need, announced today that it intends to offer and sell, subject to market and other conditions, approximately $175 million of its ordinary shares in a global offering, which is comprised of a public offering in the United States and Canada of ordinary shares in the form of American Depositary Shares ("ADS"), and an offer of ordinary shares in Europe and countries outside of the United States and Canada in a concurrent private placement. Investors other than qualified investors under applicable law will not be eligible to participate in this private placement.

19
Oct
2017

Kankercongres.be: Meer dan 300 deelnemers krijgen op 21 oktober meer informatie over kankeronderzoek en toekomstige behandelingen

Meer dan 300 patiënten, artsen, wetenschappers en industrievertegenwoordigers komen op 21 oktober naar Gent voor het eerste kankercongres. Inschrijvingen lopen nog tot 20 oktober of ter plaatse.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

E-letter archive

UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.

Interested in a regular update of the Life Sciences and biotech sector in Flanders?